The U.S. launch of a biosimilar to AbbVie’s Humira appears to be hurting the copycat’s developer itself. After AbbVie reported a Humira U.S. sales decline of 26% in the first quarter, Amgen said its ...

Application error: a client-side exception has occurred (see the browser console for more information).

AbbVie is on the rebound after a sell-off on concerns about the pending FDA decision for a biosimilar drug. Humira and Enbrel are among the top-selling drugs to be copycatted but biosimilars are ...

Non-medical switching policies that mandate biosimilar use for inflammatory arthritis do not appear to increase the use of ...

Shares of the immunology juggernaut AbbVie (NYSE: ABBV) were down by 4% on sky-high volume as of 11 a.m. ET Thursday. That's equivalent to a $7 billion drop in market capitalization. What's spooking ...

(Reuters) - Amgen Inc's version of AbbVie Inc's Humira arthritis drug, the world's top-selling medicine, appears similar in potency and safety to the original product, U.S. Food and Drug ...

(Reuters) - Amgen Inc's cheaper version of AbbVie's top-selling arthritis drug Humira is highly similar to the original and should be approved, an advisory panel to the U.S. Food and Drug ...

About 1.5 million Americans suffer from rheumatoid arthritis, a chronic disease in which the immune system attacks healthy cells, typically around the joints, causing swelling and deformity. Generally ...

Today, Coherus and Mark Cuban announced a partnership to launch an ultra-low-priced Humira biosimilar. This steep discount might have negative consequences for both AbbVie and Amgen later on this year ...